MONTE ROSA THERAPEUTICS INC. - COMMON STOCK

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

17 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 2023 06:15:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

26 Jul 2023 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

30 May 2023 15:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

23 May 2023 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

17 Apr 2023 15:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

23 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

16 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

03 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

09 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 06:30:01 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

10 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

01 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

31 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

20 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader

06 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

11 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

11 May 2022 06:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

08 Apr 2022 12:00:00 By Nasdaq GlobeNewswire